Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C37H55FN10O13 |
| Molecular Weight | 865.8927 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC([18F])C(=O)NC[C@@H]1O[C@@H]([C@H](O)[C@H](O)[C@H]1O)C(=O)NCCCC[C@@H]2NC(=O)[C@@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC2=O
InChI
InChIKey=VZVYOBLEVYIWBA-ZIILNSDKSA-N
InChI=1S/C37H55FN10O13/c1-18(38)31(55)43-16-24-27(52)28(53)29(54)30(61-24)36(60)41-12-6-5-10-21-33(57)46-20(11-7-13-42-37(39)40)32(56)44-17-25(49)45-23(15-26(50)51)35(59)48-22(34(58)47-21)14-19-8-3-2-4-9-19/h2-4,8-9,18,20-24,27-30,52-54H,5-7,10-17H2,1H3,(H,41,60)(H,43,55)(H,44,56)(H,45,49)(H,46,57)(H,47,58)(H,48,59)(H,50,51)(H4,39,40,42)/t18?,20-,21-,22+,23-,24-,27-,28+,29+,30-/m0/s1/i38-1
| Molecular Formula | C37H55FN10O13 |
| Molecular Weight | 865.8927 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 10 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 17:00:13 GMT 2025
by
admin
on
Tue Apr 01 17:00:13 GMT 2025
|
| Record UNII |
3LB34F4XDZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3LB34F4XDZ
Created by
admin on Tue Apr 01 17:00:13 GMT 2025 , Edited by admin on Tue Apr 01 17:00:13 GMT 2025
|
PRIMARY | |||
|
345660-07-3
Created by
admin on Tue Apr 01 17:00:13 GMT 2025 , Edited by admin on Tue Apr 01 17:00:13 GMT 2025
|
PRIMARY | |||
|
131801081
Created by
admin on Tue Apr 01 17:00:13 GMT 2025 , Edited by admin on Tue Apr 01 17:00:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
((18)F)Galacto-RGD PET identified 10 of 12 tumors, with SUVs ranging from 2.2 to 5.8 (mean, 3.4 For radiolabeling of the glycopeptide, 4-nitrophenyl-2-(18F)fluoropropionate was used. This prosthetic group allowed synthesis of (18F)Galacto-RGD with a maximum decay-corrected radiochemical yield of up to 85% and radiochemical purity >98%. The overall radiochemical yield was 29 +/- 5% with a total reaction time including final HPLC preparation of 200 +/- 18 min. Despite the time-consuming synthesis of the prosthetic group 185 MBq of (18F)Galacto-RGD, a sufficient dose for patient studies, can be produced starting with approximately 2.2 GBq of (18F)flouride. Moreover, the fast excretion, the suitable metabolic stability and the low estimated radiation dose allow to evaluate this tracer in human studies.
|
||
|
ACTIVE MOIETY |
((18)F)Galacto-RGD PET identified 10 of 12 tumors, with SUVs ranging from 2.2 to 5.8 (mean, 3.4 +/- 1.2). Two tumors <5 mm were missed. Tumor/blood and tumor/muscle ratios were 2.8 +/- 1.1 and 5.5 +/- 1.6, respectively. Tumor kinetics was consistent with a two-tissue compartmental model with reversible specific binding. Immunohistochemistry confirmed alphavbeta3 expression in all tumors with alphavbeta3 being located on the microvessels in all specimens and additionally on tumor cells in one specimen. Image fusion of ((18)F)Galacto-RGD PET with magnetic resonance imaging/multislice CT and definition of tumor subvolumes was feasible in all cases. ((18)F)Galacto-RGD PET allows for specific imaging of alphavbeta3 expression in SCCHN with good contrast. Image fusion and definition of tumor subvolumes is feasible. This technique might be used for the assessment of angiogenesis and for planning and response evaluation of alphavbeta3-targeted therapies.
|
